Mindray Medical announces completion of Wuhan Dragonbio acquisition

Mindray Medical International Limited ("Mindray" or the "Company", NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today that it completed the acquisition of the remaining stake in Wuhan Dragonbio Surgical Implant Co., Ltd. (the "Dragonbio") for a total cash consideration of RMB 435 million (approximately US$ 70.2 million) pursuant to the terms of the definitive agreement entered into on July 7, 2015. The Company now holds 100% of Dragonbio. Dragonbio is a domestic medical orthopedic products provider that specializes in trauma, spine, joint and other surgical products.

Source:

Mindray Medical International Limited

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mindray. (2019, June 20). Mindray Medical announces completion of Wuhan Dragonbio acquisition. News-Medical. Retrieved on October 11, 2024 from https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx.

  • MLA

    Mindray. "Mindray Medical announces completion of Wuhan Dragonbio acquisition". News-Medical. 11 October 2024. <https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx>.

  • Chicago

    Mindray. "Mindray Medical announces completion of Wuhan Dragonbio acquisition". News-Medical. https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx. (accessed October 11, 2024).

  • Harvard

    Mindray. 2019. Mindray Medical announces completion of Wuhan Dragonbio acquisition. News-Medical, viewed 11 October 2024, https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mindray first quarter net revenues increase 21.1% to $219.0 million